Ovarian cancer

Active Research Protocols

  1. 00-C-0018 – A Pilot Study of Proteomic Evaluation of Epithelial Ovarian Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile Associated with Relapse
  2. 00-C-0121 – A Phase I Investigation of IL-12/Pulse IL-2 in Adults with Advanced Solid Tumors
  3. 01-C-0008 – Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Pilot Study
  4. 02-C-0212 – Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
  5. 02-C-0268 – Prospective Study of Prophylactic Salpingo-Oophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer
  6. 04-C-0232 – A Multi-Institutional Study of Proteomic Evaluation of Epithelial Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile of Relapse
  7. 04-C-0246 – An Open Label Pilot Study to Evaluate the Safety and Tolerability of PANVAC-V (Vaccinia) and PANVAC-F (Fowlpox) in Combination with Sargramostim in Adults with Metastatic Carcinoma
  8. 07-C-0058 – A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer
  9. 07-C-0061 – Phase II Study of Clinical Activity and Proteomic Pathway Profiling of the VEGFR2 Inhibitor, ZD6474 (Vandetanib) in Women with Relapsed or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
  10. 08-C-0092 – A Phase I Study with an Expansion Cohort of the PARP Inhibitor AZD2281 Combined with Carboplatin in BRCA1/2 Familial Breast and Ovarian Cancer and Sporadic Triple Negative Breast and Ovarian Cancer
  11. 09-C-0089 – A Targeted Ph I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ยจ), in Adults with Solid Tumors with a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Ca (MTC)
  12. 10-C-0189 – A Phase 1, Dose Escalation Study of MGAH22 (Fc-Optimized Chimeric Anti-HER2 Monoclonal Antibody) in Patients with Refractory HER2 Positive Breast Cancer and Patients with Other HER2 Positive Carcinomas for Whom no Standard Therapy is Available
  13. 11-C-0022 – A Pharmacokinetic/Pharmacodynamic Study with a Phase I Run-In with a PARP Inhibitor (Olaparib) in Combination with Carboplatin for Refractory or Recurrent Women's Cancers
  14. 11-C-0033 – Extended Follow-up of High Ovarian Cancer Risk Cohort from 02-C-0268 (GOG-199)
  15. 11-C-0061 – Phase I Trial of Z-Endoxifen in Adults with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid Tumors
  16. 11-C-0080 – Ph II Randomized Trial of the Combination of ABT-888 with Metronomic Oral Cyclophosphamide in Refractory BRCA-Pos Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-Neg Breast Cancer, and Low-Grade NHL
  17. 11-C-0140 – A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients with Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors
  18. 11-C-0212 – A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin over Expressing Cancers
  19. 11-C-0242 – Collection of Blood from Patients with Cancer for Analysis of Genetic Differences in Drug Disposition
  20. 12-C-0008 – An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of the Antimesothelin Antibody Drug Conjugate BAY 94-9343 in Subjects with Advanced Solid Tumors
  21. 12-C-0081 – Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
  22. 12-C-0191 – Phase II Open Label Non-Randomized Single Agent Study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-Mimetic Birinapant (TL32711; NSC 756502) in Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary Peritoneal
  23. 13-C-0036 – A Pilot Study of [18F]-CP18 PET/CT Imaging in Patients With Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Therapy Receiving Birinapant, a SMAC Mimetic Therapy
  24. 95-C-0055 – A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin with G-CSF for Patients with Newly Diagnosed Advanced Stage Ovarian Cancer
  25. 95-HG-0165 – Outcomes of Education and Counseling for HNPCC / Lynch Syndrome Testing
  26. 99-C-0081 – Methods in Education for Breast Cancer Genetics
NOTE: PDF documents require the free
Adobe Reader.
This page was last updated: January 24, 2014